Literature DB >> 17181151

2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity.

Mathew P Leese1, Bertrand Leblond, Andrew Smith, Simon P Newman, Anna Di Fiore, Giuseppina De Simone, Claudiu T Supuran, Atul Purohit, Michael J Reed, Barry V L Potter.   

Abstract

The anticancer activities and SARs of estradiol-17-O-sulfamates and estradiol 3,17-O,O-bis-sulfamates (E2bisMATEs) as steroid sulfatase (STS) inhibitors and antiproliferative agents are discussed. Estradiol 3,17-O,O-bis-sulfamates 20 and 21, in contrast to the 17-O-monosulfamate 11, proved to be excellent STS inhibitors. 2-Substituted E2bisMATEs 21 and 23 additionally exhibited potent antiproliferative activity with mean graph midpoint values of 18-87 nM in the NCI 60-cell-line panel. 21 Exhibited antiangiogenic in vitro and in vivo activity in an early-stage Lewis lung model, and 23 dosed p.o. caused marked growth inhibition in a nude mouse xenograft tumor model. Modeling studies suggest that the E2bisMATEs and 2-MeOE2 share a common mode of binding to tubulin, though COMPARE analysis of activity profiles was negative. 21 was cocrystallized with carbonic anhydrase II, and X-ray crystallography revealed unexpected coordination of the 17-O-sulfamate of 21 to the active site zinc and a probable additional lower affinity binding site. 2-Substituted E2bisMATEs are attractive candidates for further development as multitargeted anticancer agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17181151     DOI: 10.1021/jm060705x

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  30 in total

1.  Quantitative proteomic analysis revealed lovastatin-induced perturbation of cellular pathways in HL-60 cells.

Authors:  Xiaoli Dong; Yongsheng Xiao; Xinning Jiang; Yinsheng Wang
Journal:  J Proteome Res       Date:  2011-10-21       Impact factor: 4.466

Review 2.  Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding.

Authors:  Vijay M Krishnamurthy; George K Kaufman; Adam R Urbach; Irina Gitlin; Katherine L Gudiksen; Douglas B Weibel; George M Whitesides
Journal:  Chem Rev       Date:  2008-03       Impact factor: 60.622

3.  Tetrahydroisoquinolinone-based steroidomimetic and chimeric microtubule disruptors.

Authors:  Mathew P Leese; Fabrice L Jourdan; Meriel R Major; Wolfgang Dohle; Ernest Hamel; Eric Ferrandis; Ann Fiore; Philip G Kasprzyk; Barry V L Potter
Journal:  ChemMedChem       Date:  2013-10-09       Impact factor: 3.466

4.  Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.

Authors:  Robert D Bruno; Tadas S Vasaitis; Lalji K Gediya; Puranik Purushottamachar; Abhijit M Godbole; Zeynep Ates-Alagoz; Angela M H Brodie; Vincent C O Njar
Journal:  Steroids       Date:  2011-06-24       Impact factor: 2.668

5.  Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health.

Authors:  Mark P Thomas; Barry V L Potter
Journal:  J Med Chem       Date:  2015-06-12       Impact factor: 7.446

6.  The In Vitro and In Vivo Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX Expression.

Authors:  Chloe Stengel; Simon P Newman; Mathew P Leese; Mark P Thomas; Barry V L Potter; Michael J Reed; Atul Purohit; Paul A Foster
Journal:  Anticancer Res       Date:  2015-10       Impact factor: 2.480

7.  Optimisation of tetrahydroisoquinoline-based chimeric microtubule disruptors.

Authors:  Wolfgang Dohle; Mathew P Leese; Fabrice L Jourdan; Christopher J Chapman; Ernest Hamel; Eric Ferrandis; Barry V L Potter
Journal:  ChemMedChem       Date:  2014-05-12       Impact factor: 3.466

8.  The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer.

Authors:  Paul A Foster; L W Lawrence Woo; Barry V L Potter; Michael J Reed; Atul Purohit
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

9.  Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents.

Authors:  C Stengel; S P Newman; M P Leese; B V L Potter; M J Reed; A Purohit
Journal:  Br J Cancer       Date:  2009-12-22       Impact factor: 7.640

10.  BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure.

Authors:  J M Day; P A Foster; H J Tutill; S P Newman; Y T Ho; M P Leese; B V L Potter; M J Reed; A Purohit
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.